A groundbreaking neuroplasticity modulator known as CTH120 has demonstrated excellent safety and tolerability in Phase I trials. The development of this drug has received a significant boost with the approval of a €2.5 million grant from the European Innovation Council (EIC) Accelerator. This funding will support preparations for Phase II trials focusing on pediatric patients with Fragile X Syndrome (FXS). CONNECTA, the organization spearheading this project, is at the forefront of innovation in this area.